NASDAQ · DXCM
DexCom, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for DXCM has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.66 | $0.69 | $0.63 | 10 |
| Dec 2026 | $0.73 | $0.76 | $0.69 | 9 |
| Mar 2027 | $0.63 | $0.70 | $0.57 | 6 |
| Jun 2027 | $0.75 | $0.81 | $0.71 | 6 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · BNK Invest · Fintel- RTTNews · Oct 28, 11:14 AM EDTDexcom To Launch G7 15 Day CGM System In Canada In November; Stock Up(RTTNews) – DexCom, Inc. (DXCM) announced that its Dexcom G7 15 Day continuous glucose monitoring (CGM) system will be available in Canada beginning in November for adults aged 18 and older living with diabetes.
- Zacks · Oct 28, 7:35 AM EDTAxoGen (AXGN) Beats Q3 Earnings and Revenue EstimatesAxoGen (AXGN) delivered earnings and revenue surprises of +50.00% and +4.17%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Oct 26, 12:59 PM EDTDexCom Gears Up to Report Q3 Results: How to Play the Stock?DXCM Q3 earnings are likely to benefit from CGM adoption, G7 15 Day uptake and wider reimbursement amid tougher international comparisons.
- Zacks · Oct 20, 9:50 AM EDTDexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT StudyDXCM's G7 delivers strong results in the CONNECT study, improving A1C levels and glucose control in non-insulin users with Type 2 diabetes, supporting CGM adoption.
- Zacks · Oct 16, 12:52 PM EDTVaso Stock Surges 149% in a Year: What's Behind the Rally?VASO is gaining from higher equipment deliveries, growing deferred commissions and a sharper healthcare focus, though partner dependence and margin pressures persist.
- Zacks · Oct 13, 12:41 PM EDTHere's Why You Should Retain DexCom Stock in Your Portfolio for NowDexCom's strong margins, G7 15-day rollout and promising pipeline support its growth outlook, but factory ramp-up costs, forex and input-price pressures pose risks.
- BNK Invest · Oct 8, 11:47 AM EDTS&P 500 Analyst Moves: DXCMThe latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, DexCom is now the #9 analyst pick, moving up by 19 spots. This rank is formed by averaging the analyst opinions for each component from each br
- Fintel · Oct 7, 11:55 AM EDTBarclays Initiates Coverage of DexCom with Overweight RatingFintel reports that on October 7, 2026, Barclays initiated coverage of DexCom (NASDAQGS:DXCM) (WBAG:DXCM) with a Overweight recommendation.This initiation follows a prior action by Barclays on May 18, 2026, when the firm maintained an Underweight rating on the stock. DexCom, Inc.
- Zacks · Oct 2, 10:00 AM EDTDXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes CareDexcom sees room to expand CGM adoption as low awareness, reimbursement hurdles and rising GLP-1 use create new opportunities in Type 2 diabetes.
- Zacks · Sep 29, 8:45 AM EDTHere's Why DexCom (DXCM) is a Strong Growth StockThe Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- RTTNews · Sep 28, 2:28 PM EDTDexcom Finds CGM Awareness And Access Challenges In Type 2 Diabetes(RTTNews) – Dexcom, Inc. (DXCM) released its 2026 State of Type 2 Report, highlighting challenges related to health literacy, technology literacy and systemic access to diabetes technology.
- MarketBeat · Sep 22, 2:25 PM EDTOura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart RingOura Inc. (NASDAQ: OURA) launched its roadshow on Sept. 21, 2026, targeting a Nasdaq debut under the ticker OURA during the week of Sept. 28. Offering 50 million shares priced between $40 and $44 each, Oura is targeting an initial market capitalization of around $12.8 billion to
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for DexCom, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.